

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Dupilumab for treating severe chronic rhinosinusitis with nasal polyps (ID6480)

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final draft guidance

(when draft guidance issued)

- | | |
|----|---|
| 1. | Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these? |
|----|---|

No additional potential equality issues were raised during consultation.
--

One issue previously raised was raised again. This was around access to dupilumab and the fact that people with severe asthma alongside their chronic rhinosinusitis with nasal polyps can already have dupilumab, while those without severe asthma cannot.
--

The committee noted this concern but concluded that because its recommendations do not have a different impact on people protected by the equality legislation than on the wider population, this was not a potential equality issue.

- | | |
|----|--|
| 2. | If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups?
If so, what are the barriers to, or difficulties with, access for the specific group? |
|----|--|

No

3.	If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No	

4.	If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?
No	

5.	Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?
Yes, in section 3.15	

Approved by Associate Director: ...Emily Crowe.....

Date: 26/09/2025